Co-Authors
This is a "connection" page, showing publications co-authored by BANU K ARUN and CONSTANCE ALBARRACIN.
Connection Strength
2.174
-
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.
Score: 0.400
-
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
Score: 0.334
-
Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
Score: 0.231
-
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
Score: 0.174
-
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
Score: 0.157
-
High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7.
Score: 0.131
-
Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.
Score: 0.120
-
Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8.
Score: 0.107
-
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.
Score: 0.100
-
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.
Score: 0.100
-
Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4.
Score: 0.083
-
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8.
Score: 0.081
-
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7).
Score: 0.049
-
Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307.
Score: 0.045
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.026
-
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88.
Score: 0.021
-
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69.
Score: 0.017